On January 16, 2014, Livzon Pharmaceutical Group Inc. (“Livzon Pharmaceutical”, A-share stock code 000513, original B-share stock code 200513) successfully launched its listing of the overseas listed foreign shares (H shares) by way of introduction on main board of Hong Kong Stock Exchange (transfer of B shares to H shares) under the stock code of 1513.The opening price of its H share had reached HKD 50.5 per share, and the closing price had reached HKD 51 per share, increasing by 34% compared with the closing price of its B share on the last B-share trading day. Such sharp growth of stock price had reflected the market recognition of Livzon Pharmaceutial and its plan of transfer of B shares to H shares.

This is the second B to H share deal in capital market after the B to H share conversion of China International Marine Containers (Group) Ltd.(“CIMC”) and also the first B to H share deal in pharmaceutical industry. Unlike the mode adopted by CIMC that underwriter acted as the H share nominal shareholder, Livzon Pharmaceutical first adopted the mode in capital market that China Securities Depository and Clearing Corporation Limited (“CSDC”) acted the H shares nominal shareholder and participated in the Central Clearing And Settlement System for the first time for H share’s transition, entrustment, settlement, etc. on behalf of the B share investors, optimizing B to H share pattern, enhancing the securityof investors’ assets, improving the efficiency of cross-board registration and settlement business and setting an example for the implement of B to H share plans.

Founded in 1985, Livzon Pharmaceutical Group Inc. is a comprehensive pharmaceutical enterprise integrating development & research, production and sales of pharmaceutical products. Successfully listed in A share market and B share market in 1993, the company became the first listed pharmaceutical company listed both in A share market and B share market.

Jingtian & Gongcheng acted as the sponsor’s PRC legal counsel.